Sangart Report issue

For profit Phase 2 Phase 3
Founded: San Diego CA United States (1998)
Status: Defunct (2013)

Organization Overview

First Clinical Trial
2003
NCT00494949
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Sangart, Inc., San Diego, CA

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acidosis (Phase 2)

Acidosis, Lactic (Phase 2)

Anemia (Phase 2)

Anemia, Sickle Cell (Phase 2)

Blood Loss, Surgical (Phase 2)

Hemoglobin C Disease (Phase 2)

Hemoglobin SC Disease (Phase 2)

Hemorrhage (Phase 2)

Hypotension (Phase 3)

Hypoxia (Phase 2)

Ischemia (Phase 3)

Shock (Phase 2)

Shock, Hemorrhagic (Phase 2)

Shock, Traumatic (Phase 2)

Vascular Diseases (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 5